Associations between attention-deficit hyperactivity disorder genetic liability and ICD-10 medical conditions in adults: Utilizing electronic health records in a Phenome-Wide Association Study - Haan, Elis; Krebs, Kristi; Võsa, Urmo; Brikell, Isabell; Larsson, Henrik; Estonian Biobank Research Team; Lehto, Kelli (medRxiv, 2023)
Background Attention-deficit hyperactivity disorder (ADHD) is often comorbid with other medical conditions in adult patients. However, ADHD is extremely underdiagnosed in adults and little is known about the medical comorbidities in undiagnosed adult individuals with high ADHD liability. In this study we investigated associations between ADHD genetic liability and electronic health record (EHR)-based ICD-10 diagnoses across all diagnostic categories, in individuals without ADHD diagnosis history.Methods We used data from the Estonian Biobank cohort (N=111,261) and generated polygenic risk scores (PRS) for ADHD (PRSADHD) based on the ADHD genome-wide association study. We performed a phenome-wide association study (PheWAS) to test for associations between standardized PRSADHD and 1,515 EHR-based ICD-10 diagnoses in the full and sex-stratified sample. We compared the observed significant ICD-10 associations to associations with: 1) ADHD diagnosis and 2) questionnaire-based high ADHD risk analyses.Results After Bonferroni correction (p=3.3×10-5) we identified 80 medical conditions associated with PRSADHD. The strongest evidence was seen with chronic obstructive pulmonary disease (OR=1.15, CI=1.11-1.18), obesity (OR=1.13, CI=1.11-1.15), and type 2 diabetes (OR=1.11, CI=1.09-1.14). Sex-stratified analysis generally showed similar associations in males and females. Out of all identified associations, 40% and 78% were also observed using ADHD diagnosis or questionnaire-based ADHD, respectively, as the predictor.Conclusions Overall our findings indicate that ADHD genetic liability is associated with an increased risk of a substantial number of medical conditions in undiagnosed individuals. These results highlight the need for timely detection and improved management of ADHD symptoms in adults.Competing Interest StatementHenrik Larsson reports receiving grants from Shire Pharmaceuticals; personal fees from and serving as a speaker for Medice, Shire/Takeda Pharmaceuticals and Evolan Pharma AB; and sponsorship for a conference on attention-deficit/hyperactivity disorder from Shire/Takeda Pharmaceuticals and Evolan Pharma AB, all outside the submitted work. All other authors report no conflicts of interest.Clinical Protocols https://osf.io/7txg2 Funding StatementThis research in the Estonian Biobank was supported by the European Union through the European Regional Development Fund (Project No 2014-2020 4.01.15 0012), and the Estonian Research Councils grant No. PSG615. This study was also funded by EU H2020 grant 692145, Estonian Research Council Grant IUT20 60, IUT24 6, and European Union through the European Regional Development Fund Project No. 2014-2020.4.01.15 0012 GENTRANSMED and 2014-2020.4.01.16 0125. This research is also part of the TIMESPAN project that has received funding from the European Unions Horizon 2020 research and innovation programme under grant agreement No 965381. This reflects only the authors view, and the European Commission is not responsible for any use that may be made of the information it contains. Henrik Larsson acknowledge financial support from the Swedish Research Council (2018-02599) and the Swedish Brain Foundation (FO2021-0115). Isabell Brikell acknowledges financial support by the Swedish Brain Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The research project has obtained approval from the Estonian Council on Bioethics and Human Research. All Estonian Biobank participants have signed an informed consent form.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAccording to the existing EU and Estonian data protection regulations, sensitive data (medical, genetic) cannot be made freely available. However, data access is possible following the standard data access procedure: https://genomics.ut.ee/en/content/estonian-biobank